The Regulation of Human Germline Genome Modification in Japan

Author(s):  
Tetsuya Ishii
Keyword(s):  
2011 ◽  
Vol 33 (7) ◽  
pp. 665-683 ◽  
Author(s):  
An XIAO ◽  
Ying-Ying HU ◽  
Wei-Ye WANG ◽  
Zhi-Peng YANG ◽  
Zhan-Xiang WANG ◽  
...  

Author(s):  
Ivana Gessara ◽  
Falk Dittrich ◽  
Moritz Hertel ◽  
Staffan Hildebrand ◽  
Alexander Pfeifer ◽  
...  

2014 ◽  
Vol 11 (4) ◽  
pp. 399-402 ◽  
Author(s):  
Bin Shen ◽  
Wensheng Zhang ◽  
Jun Zhang ◽  
Jiankui Zhou ◽  
Jianying Wang ◽  
...  

Genetics ◽  
2010 ◽  
Vol 186 (2) ◽  
pp. 451-459 ◽  
Author(s):  
Iara D. Carbery ◽  
Diana Ji ◽  
Anne Harrington ◽  
Victoria Brown ◽  
Edward J. Weinstein ◽  
...  

Author(s):  
Christophe Delenda ◽  
Sébastien Paris ◽  
Sylvain Arnould ◽  
Edward Balbirnie ◽  
Jean-Pierre Cabaniols
Keyword(s):  

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Ilya B Tikh ◽  
James C Samuelson

Abstract The ability to alter the genomic material of a prokaryotic cell is necessary for experiments designed to define the biology of the organism. In addition, the production of biomolecules may be significantly improved by application of engineered prokaryotic host cells. Furthermore, in the age of synthetic biology, speed and efficiency are key factors when choosing a method for genome alteration. To address these needs, we have developed a method for modification of the Escherichia coli genome named FAST-GE for Fast Assembly-mediated Scarless Targeted Genome Editing. Traditional cloning steps such as plasmid transformation, propagation and isolation were eliminated. Instead, we developed a DNA assembly-based approach for generating scarless strain modifications, which may include point mutations, deletions and gene replacements, within 48 h after the receipt of polymerase chain reaction primers. The protocol uses established, but optimized, genome modification components such as I-SceI endonuclease to improve recombination efficiency and SacB as a counter-selection mechanism. All DNA-encoded components are assembled into a single allele-exchange vector named pDEL. We were able to rapidly modify the genomes of both E. coli B and K-12 strains with high efficiency. In principle, the method may be applied to other prokaryotic organisms capable of circular dsDNA uptake and homologous recombination.


2019 ◽  
Vol 46 (2) ◽  
pp. 151-152 ◽  
Author(s):  
Iñigo De Miguel Beriain

Should we use human germline genome modification (HGGM) only when serious diseases are involved? This belief is the underlying factor in the article written by Kleiderman, Ravitsky and Knoppers to which I now respond. In my opinion, the answer to this question should be negative. In this paper, I attempt to show that there are no good reasons to think that this technology should be limited to serious diseases once it is sufficiently proven to be safe and efficient. In fact, opting otherwise would negatively harm human beings’ right to the highest standard of health that unmodified embryos could promote. Therefore, the issue should not be so much to define adequately what a serious disease is, but rather to elucidate whether this concept should play any role beyond the context of preimplantation genetic testing (PGT). This paper argues that we should not accept the similarity between technologies such as PGT and HGGM because they face different challenges and offer totally different possibilities. Therefore, we are in urgent need to build a completely new ethical architecture that covers the application of germline editing in human embryos. As a part of that process, a much deeper debate on the necessity of distinguishing different disease types is required.


Sign in / Sign up

Export Citation Format

Share Document